• Rifampin in Research: Applied Workflows & Troubleshooting Ti

  2026-05-21

  Rifampin, the benchmark rifamycin antibiotic, empowers researchers with precise transcription inhibition for bacterial resistance studies, synthetic biology, and antibiotic drug research. Explore advanced workflows, protocol enhancements, and troubleshooting strategies that maximize reliability and reproducibility in experimental settings.

• Biomimetic Chromatography for Modeling Pulmonary Drug Permea

  2026-05-21

  The reference study introduces robust biomimetic chromatographic techniques—IAM-LC and OT-CEC—coupled with mass spectrometry to model lung permeability for pharmaceuticals. These methods offer improved predictive power for pulmonary drug absorption and facilitate high-throughput screening, with specific relevance for anti-inflammatory corticosteroids in respiratory disease research.

• Thrombin in Fibrin Matrices: Redefining Vascular Models

  2026-05-20

  This thought-leadership article explores how the mechanistic versatility of thrombin as a trypsin-like serine protease at the heart of the coagulation cascade is driving new frontiers in translational vascular biology. By integrating recent evidence on endothelial invasion in fibrin matrices and leveraging ultra-pure reagents such as APExBIO's Coagulation Factor II (Thrombin) B Chain Fragment, we offer actionable guidance for researchers building next-generation angiogenesis and coagulation assays that bridge basic science and clinical relevance.

• Obacunone Drives Ferroptosis in Ovarian Cancer via Akt/p53 A

  2026-05-20

  This study uncovers how Obacunone, a natural compound, induces ferroptosis in ovarian cancer cells by modulating the Akt/p53 pathway. The findings highlight a mechanistic link between Akt inhibition, p53 activation, and iron-dependent cell death, offering a new direction for ovarian cancer therapy research.

• CLK2 Drives Platinum Resistance in Ovarian Cancer via BRCA1

  2026-05-19

  The reference study reveals that Cdc2-like kinase 2 (CLK2) is upregulated in ovarian cancer and confers platinum resistance by phosphorylating BRCA1, enhancing DNA repair. These insights provide a mechanistic basis for targeting CLK2 to overcome chemotherapy resistance, with significant implications for improving ovarian cancer treatment outcomes.

• Ibrexafungerp Retains Potent Activity Against Vaginal Candid

  2026-05-19

  This study demonstrates that ibrexafungerp (MK 3118) maintains potent in vitro antifungal activity against both fluconazole-susceptible and -resistant vaginal Candida isolates at acidic pH, closely mirroring the vaginal environment in vulvovaginal candidiasis (VVC). The findings highlight ibrexafungerp’s unique suitability for treating VVC, especially in cases where azole resistance limits therapeutic options.

• MALAT1/miR-125b/STAT3 Axis Regulates PCT Expression in Sepsi

  2026-05-18

  This study uncovers a mechanistic link between the long noncoding RNA MALAT1, miR-125b, and STAT3 signaling in regulating procalcitonin (PCT) expression in sepsis. By elucidating the MALAT1-mediated ceRNA network's influence on STAT3 and PCT, the work refines our understanding of sepsis biomarkers and highlights potential molecular targets for improved diagnostic and therapeutic approaches.

• Gepotidacin (GSK2140944): Transforming Antibacterial Researc

  2026-05-18

  Gepotidacin (GSK2140944) offers a first-in-class solution for combating antibiotic resistance, with a unique mode of action targeting bacterial type II topoisomerases. This article guides experimentalists through optimized workflows, troubleshooting, and advanced applications to maximize reproducibility and impact in antibacterial research.

• Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Proto

  2026-05-17

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) prevents proteolytic degradation during protein extraction and sample preparation, especially in workflows where EDTA could interfere with divalent cation-dependent assays. It is not suitable for protocols where metalloprotease inhibition via chelation is required, as it lacks EDTA.

• Evaluating Protease Inhibitor Libraries for SARS-CoV-2 Drug

  2026-05-16

  This review analyzes the design and utility of commercial protease inhibitor libraries for virtual screening and drug design, specifically in the context of SARS-CoV-2. The paper highlights gaps in design transparency, documentation, and compound diversity, impacting the reliability of these resources for high-throughput drug discovery.

• Rotavirus-Induced Downregulation of Nrf2: Mechanisms and Imp

  2026-05-15

  This study delineates how progressive rotavirus infection actively suppresses the redox-sensitive transcription factor Nrf2 and its downstream cytoprotective genes, highlighting a viral strategy to undermine host antioxidant defenses. The findings provide a mechanistic foundation for exploring Nrf2-modulating interventions in viral pathogenesis and cellular stress research.

• Fluorescein TSA Fluorescence System Kit: Amplifying Sensitiv

  2026-05-15

  The Fluorescein TSA Fluorescence System Kit delivers unrivaled sensitivity for detecting low-abundance targets in fixed cells and tissues via robust tyramide signal amplification. This article unpacks experimental workflows, real-world troubleshooting, and key innovations—translating reference study insights into actionable protocol enhancements for modern immunohistochemistry, immunocytochemistry, and in situ hybridization.

• PKH26 Red Fluorescent Cell Linker Kit: Technical Workflow Gu

  2026-05-14

  The PKH26 Red Fluorescent Cell Linker Kit enables stable, minimally toxic fluorescent labeling of cell membrane lipid regions for cell tracing and proliferation detection in vitro and in vivo. It should not be used for intracellular or non-membrane labeling applications. This kit is best suited for studies requiring long-term membrane fluorescence and reliable tracking of cell division.

• TNF-alpha Recombinant Murine Protein: Applied Cell Death Res

  2026-05-14

  Harness TNF-alpha recombinant murine protein for precise apoptosis and inflammation modeling—now with new insights from transcription-independent cell death pathways. This guide details stepwise protocols, optimization strategies, and cutting-edge applications, leveraging both classic and emerging mechanistic frameworks.

• Epalrestat in Cancer Fructose Metabolism: Next-Gen Polyol Pa

  2026-05-13

  Explore how Epalrestat, a leading aldose reductase inhibitor, is transforming oxidative stress and cancer metabolism research by precisely targeting the polyol pathway. This article uniquely bridges cutting-edge findings in fructose metabolism with advanced assay considerations.

16085 records 2/1073 page Previous Next 12345 下5页 Last page